These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

460 related items for PubMed ID: 21497782

  • 1. Outcomes after unrestricted use of everolimus-eluting stent compared to paclitaxel- and sirolimus-eluting stents.
    Mahmoudi M, Delhaye C, Wakabayashi K, Ben-Dor I, Gonzalez MA, Maluenda G, Gaglia MA, Torguson R, Xue Z, Suddath WO, Satler LF, Kent KM, Pichard AD, Waksman R.
    Am J Cardiol; 2011 Jun 15; 107(12):1757-62. PubMed ID: 21497782
    [Abstract] [Full Text] [Related]

  • 2. Three-year outcomes following sirolimus- versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the REWARDS Registry).
    Hanna NN, Gaglia MA, Torguson R, Ben-Dor I, Gonzalez MA, Collins SD, Syed AI, Maluenda G, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R.
    Am J Cardiol; 2010 Aug 15; 106(4):504-10. PubMed ID: 20691308
    [Abstract] [Full Text] [Related]

  • 3. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL, SPIRIT III Investigators.
    Circulation; 2009 Feb 10; 119(5):680-6. PubMed ID: 19171853
    [Abstract] [Full Text] [Related]

  • 4. Everolimus-eluting versus paclitaxel-eluting stents for treatment of bare metal stent restenosis.
    Almalla M, Schröder JW, Pross V, Stegemann E, Marx N, Hoffmann R.
    Am J Cardiol; 2011 Aug 15; 108(4):518-22. PubMed ID: 21624553
    [Abstract] [Full Text] [Related]

  • 5. Percutaneous coronary intervention with second-generation paclitaxel-eluting stents versus everolimus-eluting stents in United States contemporary practice (REWARDS TLX Trial).
    Waksman R, Ghali M, Goodroe R, Ryan T, Turco M, Ring M, McGarry T, Dobies D, Shammas N, Steinberg DH, Swymelar S, Kaneshige K, Torguson R.
    Am J Cardiol; 2012 Oct 15; 110(8):1119-24. PubMed ID: 22762711
    [Abstract] [Full Text] [Related]

  • 6. Comparison of long-term outcomes between everolimus-eluting and sirolimus-eluting stents in small vessels.
    Kitabata H, Loh JP, Sardi GL, Badr S, Dvir D, Barbash IM, Pendyala LK, Minha S, Torguson R, Chen F, Satler LF, Suddath WO, Kent KM, Pichard AD, Waksman R.
    Am J Cardiol; 2013 Apr 01; 111(7):973-8. PubMed ID: 23337837
    [Abstract] [Full Text] [Related]

  • 7. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW.
    JACC Cardiovasc Interv; 2013 Sep 01; 6(9):914-22. PubMed ID: 24050859
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.
    Simsek C, Räber L, Magro M, Boersma E, Onuma Y, Stefanini GG, Zanchin T, Kalesan B, Wenaweser P, Jüni P, van Geuns RJ, van Domburg RT, Windecker S, Serruys PW.
    Int J Cardiol; 2013 Dec 05; 170(1):36-42. PubMed ID: 24196314
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Two-year outcome of patients treated with sirolimus- versus paclitaxel-eluting stents in an unselected population with coronary artery disease (from the REWARDS Registry).
    Roy P, Bonello L, de Labriolle A, Okabe T, Pinto Slottow TL, Steinberg DH, Torguson R, Smith K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R.
    Am J Cardiol; 2008 Aug 01; 102(3):292-7. PubMed ID: 18638589
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
    Lee CW, Park DW, Lee SH, Kim YH, Hong MK, Kim JJ, Park SW, Yun SC, Seong IW, Lee JH, Lee NH, Cho YH, Cheong SS, Lim DS, Yang JY, Lee SG, Kim KS, Yoon J, Jeong MH, Seung KB, Hong TJ, Park SJ, ZEST-AMI Investigators.
    Am J Cardiol; 2009 Nov 15; 104(10):1370-6. PubMed ID: 19892052
    [Abstract] [Full Text] [Related]

  • 15. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J.
    Circulation; 2012 Jun 12; 125(23):2873-91. PubMed ID: 22586281
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Safety and efficacy outcomes of overlapping second-generation everolimus-eluting stents versus first-generation drug-eluting stents.
    Kitabata H, Loh JP, Pendyala LK, Badr S, Dvir D, Barbash IM, Minha S, Torguson R, Chen F, Satler LF, Suddath WO, Kent KM, Pichard AD, Waksman R.
    Am J Cardiol; 2013 Oct 15; 112(8):1093-8. PubMed ID: 23827397
    [Abstract] [Full Text] [Related]

  • 18. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries).
    Daemen J, Tanimoto S, García-García HM, Kukreja N, van de Sande M, Sianos G, de Jaegere PP, van Domburg RT, Serruys PW.
    Am J Cardiol; 2007 Apr 15; 99(8):1027-32. PubMed ID: 17437722
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of everolimus-eluting stents for bare-metal in-stent restenosis.
    Ota H, Mahmoudi M, Torguson R, Satler LF, Suddath WO, Pichard AD, Waksman R.
    Cardiovasc Revasc Med; 2015 Apr 15; 16(3):151-5. PubMed ID: 25977226
    [Abstract] [Full Text] [Related]

  • 20. Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents.
    Elezi S, Dibra A, Mehilli J, Pache J, Wessely R, Schömig A, Kastrati A.
    J Am Coll Cardiol; 2006 Oct 03; 48(7):1304-9. PubMed ID: 17010786
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.